Preclinical development of new tetrahydrofuran derivatives targeting the sigma-1 chaperone protein as neuroprotectants in Alzheimer’s disease.
The novel tetrahydrofuran derivative ANAVEX2-73 attenuated GSK-3β activation and Tau hyperphosphorylation in a nontransgenic Alzheimer’s disease model in mice.
